



1

Disclaimer


This presentation contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this presentation. The Group is providing the information in this presentation as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

The availability and indications/claims of the products illustrated and mentioned in this presentation may vary according to country.

2

straumanngroup

2



Agenda

[Full-year highlights](#)


[Business and regional review](#)

[Recent achievements & strategy in action](#)

[Outlook 2020](#)

[Q&A and upcoming events](#)

3




Full-year highlights

Guillaume Daniellot, CEO

straumanngroup

4

Excellent growth and further margin expansion



5


¹ Organic growth = excluding effects of currencies and business combinations ² Core figures exclude one-time M&A effects, exceptional pension-plan items, restructuring and non-recurring litigation expenses, amortization and impairment of goodwill and acquisition related intangible assets. ³ Outlook expectations barring unforeseen events/circumstances and excluding FX and the coronavirus impact)

straumanngroup

5

Strong fourth quarter despite high baseline

Organic revenue growth




6


straumanngroup

6

Continued value creation for shareholders




Impressive 5-year performance



¹ Core figures as of 2018; prior year figures exclude exceptional effects

Leadership in implant dentistry extended





¹ Implant dentistry market segment includes implant fixtures, final and temporary abutments, healing screws, copings and related instruments; information based on Decision Resources Group and Straumann data.

straumanngroup

9

1636 new talents



¹ Mainly Anthogyr, Digital Planning Service, Yllier Biomaterials, Bay Materials

straumanngroup

10

Business and regional review


Peter Hackel, CFO

straumanngroup


11

Double-digit growth across all regions

Revenue development (in CHF m, rounded)



Regional share of organic growth



straumanngroup


12

BLX boost in EMEA & North America


EMEA



Revenue change (organic)



North America



- **EMEA Q4:** slight sequential increase despite exceptional Q4 2019.
- Lifted by BLX and value-brand roll-outs.
- Germany solid; strong increases in Italy, Middle East, Russia, Spain and Turkey.
- **NAM: Q4:** US and Canada continue to perform well.
- Growth underpinned by BLT and boosted by BLX; good progress in non-premium franchise with Neodent GM.
- Clear-aligner business continues to grow strongly throughout region.

straumanngroup

13


13

Asia Pacific dynamic; Latin America exceptional


APAC



Revenue change (organic)



Latin America



- **APAC Q4:** premium implants are the main driver; strong scanner sales in China.
- Value brands add lift (Anthogyr in China; Neodent in Japan & Thailand).
- China dynamic pre-coronavirus; Australia, Japan, Korea & Thailand out-perform; joint venture in Hong Kong.
- **LATAM Q4:** exceptional performance in unstable environment (+13% in shadow of surge in prior Q4).
- Neodent, Straumann, biomaterials & ClearCorrect drive performance.
- Good growth in negative Brazilian market; Mexico dynamic lifted by Neodent GM launch.

straumanngroup

14

14

All businesses report continued strong growth

Implant systems




Digital & restorative



Biomaterials



Orthodontics



15

straumanngroup

15

Overview of non-core items

The following effects were defined as non-core items:

2018

- The Batigroup acquisition led to an exceptional inventory-revaluation expense of CHF 8.8m, reported under 'costs of goods sold', as well as a tax benefit of CHF 1.9m
- Amortization of acquisition-related intangible assets of CHF 16m (EBIT level)
- Consolidation gains of CHF 11m related to the acquisition of former associates (below EBIT)
- Impairment investment in RODO Medical of CHF 8m (below EBIT)

2019

- The Align Technology patent dispute settlement charge of CHF 26m or CHF 22m after tax deduction (administrative expense)
- Fire damages at Dental Wings of CHF 4m (COGS) and CHF 3m (administrative expense); the insurance coverage to date amounts to CHF 7m (other income)
- Amortization of acquisition-related intangible assets of CHF 19m (EBIT level)
- Consolidation gains of CHF 6m related to the acquisition of former associates (below EBIT)

16

straumanngroup

16

Core financials at a glance

| In CHF m, rounded | FY 2019 | % of revenue | Margin change | Change in % | Comments |
|---------------------|----------------|--------------|----------------|--------------|--|
| Revenue | 1'596.2 | 100.0% | | 17.1% | |
| COGS | (389.0) | 24.4% | | (16.0%) | |
| GROSS PROFIT | 1'207.2 | 75.6% | 20bps | 17.4% | |
| Operating expenses | (775.3) | 48.6% | | (17.4%) | |
| EBIT | 431.9 | 27.1% | 20bps | 17.6% | FX headwind -60bps IFRS16 +25bps |
| Financial result | (24.6) | 1.5% | | (45.1%) | 6.6m additional interest expenses due to IFRS16 |
| Associates | (3.0) | 0.2% | | (32.2%) | |
| Income tax | (66.0) | 4.1% | | (19.5%) | |
| NET PROFIT | 338.2 | 21.2% | (30bps) | 15.5% | |
| Basic EPS | 21.21 | | | 16.8% | |

17

straumanngroup

17

Reported financials at a glance

| In CHF m, rounded | FY 2019 | % of revenue | Margin change | Change in % | Comments |
|---------------------|----------------|--------------|-----------------|--------------|--|
| Revenue | 1'596.2 | 100.0% | | 17.1% | |
| COGS | (395.7) | 24.8% | | (14.9%) | Fire damage at Dental Wings |
| GROSS PROFIT | 1'200.5 | 75.2% | 50bps | 17.8% | |
| Operating expenses | (813.3) | 51.0% | | (20.2%) | Align patent settlement costs |
| EBIT | 387.1 | 24.3% | (90bps) | 13.0% | FX headwind -60bps IFRS16 +25bps |
| Financial result | (24.6) | 1.5% | | (45.1%) | 6.6m additional interest expenses due to IFRS16 |
| Associates | 2.9 | 0.2% | | (296%) | Full consolidation of former associates |
| Income tax | (57.4) | 3.6% | | (18.1%) | |
| NET PROFIT | 308.0 | 19.3% | (110bps) | 10.9% | |
| Basic EPS | 19.33 | | | 12.1% | |

18

straumanngroup

18


| CORE RESULT RECONCILIATION 2019 | | | | | | | CORE RESULT RECONCILIATION 2018 | | | | | | |
|--|-----------|------------------|-------------|-------------|--|---------|---------------------------------|------------------|-------------|-------------|--|-----------|-----------|
| (in CHF 1 000) | IFRS 2019 | PPA amortization | Impairments | Legal cases | Consolidation result former associates | Other | IFRS 2018 | PPA amortization | Impairments | Legal cases | Consolidation result former associates | Other | CORE 2018 |
| Revenue | 1 396 225 | | | | | | 1 363 560 | | | | | | 1 363 560 |
| Cost of goods sold | (390 760) | 2 484 | | | | 4 272 | (344 315) | 8 887 | | | | (168 992) | (395 429) |
| Gross profit | 1 005 465 | (2 484) | | | | (4 272) | 1 019 245 | (8 887) | | | | 1 207 218 | 1 028 132 |
| Other income | 12 807 | | | | | (7 085) | 3 424 | | | | | (5 732) | 3 424 |
| Distribution expense | (329 394) | (10 990) | | | | | (291 018) | 10 033 | | | | (320 594) | (280 984) |
| Administrative expense | (405 170) | 6 421 | | 25 500 | | 2 796 | (389 016) | 5 871 | | | | (460 454) | (383 145) |
| Operating profit | 387 140 | (19 294) | | 25 500 | | (17) | 342 635 | (24 791) | | | | (481 917) | 367 426 |
| Finance income | 54 873 | | | | | | 72 852 | | | | | | 72 852 |
| Finance expense | (89 475) | | | | | | (89 802) | | | | | | (89 802) |
| Gain on consolidation of former associates | 5 967 | | | | (5 967) | | 10 725 | | | (10 725) | | | 0 |
| Share of results of associates | (9 036) | | | | | | (9 984) | | 7 688 | | | | (2 296) |
| Profit before income tax | 365 468 | (19 294) | | 25 500 | (5 967) | (17) | 326 426 | (24 791) | 7 688 | | (10 725) | | 348 180 |
| Income tax expense | (57 440) | (5 416) | | (3 188) | | 5 | (48 639) | (6 611) | | 0 | | | (55 250) |
| NET PROFIT | 308 028 | (24 710) | | 22 313 | (5 967) | (13) | 277 787 | (31 402) | 7 688 | | (10 725) | | 292 930 |
| Attributable to: | | | | | | | | | | | | | |
| Shareholders of the parent company | 308 028 | (24 710) | | 22 313 | (5 967) | (13) | 277 787 | (31 402) | 7 688 | | (10 725) | | 287 318 |
| Non-controlling interests | 0 | 0 | | 0 | 0 | 0 | 0 | 0 | 0 | | 0 | | 5 612 |
| Basic earnings per share (in CHF) | 10.33 | | | | | | 17.24 | | | | | | 18.16 |
| Diluted earnings per share (in CHF) | 10.08 | | | | | | 17.18 | | | | | | 18.09 |
| Operating profit | 387 140 | (19 294) | | 25 500 | | (17) | 342 635 | (24 791) | | | | | 367 426 |
| Depreciation & amortization | 53 498 | (16 956) | | | | (3 520) | 52 367 | (15 980) | | | | | 36 387 |
| EBITDA | 440 638 | (36 250) | | 25 500 | | (3 537) | 395 002 | (40 771) | | | | | 403 813 |

19

straumanngroup

CADCAM & clear-aligner sales lift gross margin

In %, rounded




20

straumanngroup

Further improvement in core EBIT

In %, rounded




21

straumanngroup

21

Operational improvements boost core net profit

In CHF m




22

straumanngroup

22

Further improvement of the free cash flow margin

In CHF m



23

straumanngroup

23

CHF 120m invested in production expansion

ANDOVER (USA)

Straumann implant system

+3 000m²

+60% PRODUCTION CAPACITY

MONTREAL (CANADA)

Dental Wlago scanners

4 000m²

+40% PRODUCTION CAPACITY

ROUND ROCK (USA)

ClearCorrect clear aligners

+3 250m²

+60% PRODUCTION CAPACITY

CURITIBA (BRAZIL)

Neodent and novo implant systems; ClearCorrect clear aligners

+11 000m²

+35% PRODUCTION CAPACITY

OBERREICHENBACH (GERMANY)

Medentika prosthodontics and implants

+11 000m²

+50% PRODUCTION CAPACITY

MARKKLEEBERG (GERMANY)

Straumann CAD/CAM; ClearCorrect clear aligners

+1 600m²

+35% PRODUCTION CAPACITY

VILLERET (SWITZERLAND)

Straumann implant system

+16 100m²

+70% PRODUCTION CAPACITY

MENDARO (SPAIN)

CAD/CAM prosthodontics

+1 300m²

+70% PRODUCTION CAPACITY



24


* Expected production capacity increase

straumanngroup

24

Dividend raised

- The Board proposes a dividend increase to CHF 5.75 per share (prior year: CHF 5.25)
- Dividend is payable on 15 April 2020 (ex-dividend date: 9 April 2020)



25

straumanngroup

25

Recent achievements & strategy in action

Guillaume Daniellot, CEO

straumanngroup

26

Strong performance confirms our strategy



Drive high performance Straumann Group culture and organization



Target unexploited growth markets & segments



Become the total solution provider for esthetic dentistry

27

straumanngroup

27

Execution – focus on four areas

| | Market | Share | Key opportunities |
|---------|--|-------|---|
| PREMIUM | CHF 2.2bn | 44% | 1 in 4 implants fully tapered; 6% share in fully-tapered premium |
| VALUE | CHF 2.4bn | 10% | Gain share outside Brazil; all price points covered; fully competitive |
| ORTHO | CHF 3.2bn | 2% | Market growing 20+%; many entrants; expand & gain share. |
| DIGITAL | Equipment CHF 1.6bn Prosthetics CHF 4.0bn | 3% | Intra oral scanner penetration (20%) expected to grow strongly; large addressable user base |

28

straumanngroup

28

PREMIUM

BLX well received: >100 000 sold in 2019

EMEA

- Most markets: Q1/2 2019 ✓
- Russia: 2021
- Turkey: 2020

NAM

- USA/Canada: Q3 2019 ✓

LATAM

- Brazil: Q1/Q2 2019 ✓
- Mexico: 2020*
- Colombia: 2020*

APAC

- Aus./NZ: Q1 2019 ✓
- China: 2021*
- Japan: 2020*
- Korea: 2020*



Straumann's team in Thailand prepares the first launch in Asia

29

* Pending regulatory approvals

straumanngroup

29

VALUE

Simplicity, versatility and affordability – one tapered design matching all customer preferences

nubo™

Simplicity made accessible.

First launch: LATAM Q1



30

Dedicated business unit reflects high potential and strategic importance of orthodontics


- Incorporates our ClearCorrect, Smyletec and Genova clear-aligner brands as well as the recently acquired Bay Materials thermoplastics business.
- 800 employees worldwide
- Camila Finzi joins Group's Executive Management from Alcon to lead the new business unit.



Clear-aligner business growing rapidly



- Market estimated at CHF 3.2bn and growing >20% p.a.
- 2019: customer base expands >20%; case growth >60%
- Capacity fully absorbed by strong growth in NAM; full releases in Europe, LATAM & APAC now starting
- Acquisitions of Digital Planning Service, Yller and Bay Materials secure elements for success



Building a powerful team for a broader digital ecosystem


- New dedicated Digital Business Unit includes intraoral and laboratory scanners, centralized CAD/CAM prosthetics, milling equipment, 3D printers and materials, prosthetic design, guided surgery software, and planning services.
- 500 employees worldwide
- Dirk Reznik joins Straumann's Executive Management from Thermomix to lead new business unit.



33

33

'Smile in a Box' – guided surgery & prosthetic design made simple, efficient and convenient



- Enables clinicians to offer implant treatment using a fully guided digital workflow but without investing in equipment and special digital training
- Covers all surgical and prosthetic indications from single-tooth to fully edentulous restorations and from straight-forward to complex cases
- Modular service to suit customer's individual needs
- All components ordered are delivered in one box for the day of surgery




straumanngroup

34

34

Strong leadership team with broad skills and diverse backgrounds



35

35

Set for the future – first-class production organization and strong Research, Development & Operations team



- Gerhard Bauer retires after a distinguished career at Straumann
- Mark Johnson joins Executive Management team as Head RD&O
- Highly experienced executive engineer with a strong track record in manufacturing and operations, in medical devices and other fields
- Career includes leadership roles in operations at Eprexia, Medtronic and Philips Electronics Oral Healthcare



36

straumanngroup

36

Outlook 2020

straumanngroup

37

Coronavirus – dealing with the unforeseeable

- Public hospitals and dental clinics in China treating emergency / life-threatening conditions only
- Private dental practices closed
- Travel restricted in most cities
- Straumann Group has 350 employees in China; 10 in Wuhan City; none infected.
- Staff, customer and patient safety are paramount. Team in China instructed not to travel and to work from home. Precautionary instructions issued to global workforce, including travel restrictions to and from Asia.
- On the basis of the current situation, the Group believes that the impact of the virus may reduce its net revenue in Q1 2020 by approx. CHF 30m or more.

38

straumanngroup

38

Our 2020 guidance (Barring unforeseen circumstances)

| | |
|---------------|---|
| Market growth | Global implant market to continue growing at 4-5% |
| Our growth | Confident of gaining market share and achieving organic revenue growth in the low double-digit percentage range |
| Profitability | Stable core EBIT margin excluding the impact of currency fluctuations and the coronavirus |



39

straumanngroup

39

Questions & answers

Q&A

straumanngroup

40



41

Calendar of upcoming events

| 2020 | Event | Location |
|-------------------|---|------------------------------|
| 19 February | Investor meetings | London |
| 20 February | Investor meetings | Paris |
| 21 February | Investor meeting | Geneva |
| 03 March | Morgan Stanley Medtech conference | London |
| 10 March | Investor meetings | Montreal |
| 11 March | Investor meetings | New York |
| 12 March | Investor meetings | Chicago |
| 26 March | Investor meetings | Zurich |
| 27 March | Kepler Cheuvreux conference | Zurich |
| 07 April | AGM 2020 | Basel Congress Center |
| 09 April | Dividend ex-date | |
| 30 April | First-quarter results | Webcast |
| 13 May | Investor meetings | Singapore |
| 09-10 June | MainFirst Swiss Equity conference | Interlaken |
| 13 August | First-half 2020 results conference | Basel, HQ |
| 28 October | Third-quarter results | Webcast |

42

straumanngroup

42

Impact from IFRS 16 (Leases) adoption in 2019

| IFRS 16 impact (in CHF million) ¹ | Total |
|--|-------|
| Revenue | |
| Gross profit | +0.5 |
| EBITDA | +28.2 |
| EBIT | +4.1 |
| Financial results | -6.6 |
| Net profit | -2.5 |

43

43

Growth strategy pays off

| in CHF m | 2015 | 2016 | 2017 restated | | 2018 Core | 2019 Core | 5-year average |
|------------------------------------|--------------|--------------|------------------|------------------------------------|--------------|--------------|---------------------|
| Revenue | 798.6 | 917.5 | 1112.1 | Revenue | 1363.6 | 1596.2 | |
| Organic revenue growth in % | 9.1 | 13.1 | 15.7 | Organic revenue growth in % | 18.9 | 17.1 | 14.8 |
| Acquisition effect in % | 9.5 | 0.8 | 4.1 | Acquisition effect in % | 4.2 | 2.5 | 4.2 |
| Change in l.c.% | 18.6 | 13.9 | 19.8 | Change in l.c.% | 23.1 | 19.6 | 19.0 |
| FX effect in % | -6.1 | 1.0 | 1.4 | FX effect in % | -0.5 | -2.5 | -1.3 |
| Growth in CHF % | 12.4 | 14.9 | 21.2 | Growth in CHF % | 22.6 | 17.1 | 17.6 |
| | 2015 | 2016 | 2017 | | 2018 | 2019 | CAGR 2015-19 |
| Gross profit excl. exceptionals | 628.0 | 718.5 | 842.4 | Core gross profit | 1028.1 | 1207.2 | 17.7 |
| Underlying margin | 78.6% | 78.3% | 75.8% | Margin | 75.4% | 75.6% | |
| EBITDA excl. Exceptionals | 0 | 0.0 | 0.0 | Core EBITDA | 0.0 | 504.9 | |
| Underlying margin | 0.0% | 0.0% | 0.0% | Margin | 0.0% | 31.6% | |
| EBIT excl. exceptionals | 185.7 | 227.2 | 285.6 | Core EBIT | 367.4 | 431.9 | 23.5 |
| Underlying margin | 9.2% | 11.3% | #WERT! | Margin | 26.9% | 27.1% | |
| Underlying net profit | 144.7 | 186.8 | 229.7 | Core net profit | 292.9 | 338.2 | 23.6 |
| Underlying margin | 7.2% | 9.3% | 20.7% | Margin | 21.5% | 21.2% | |
| Earnings per share (adjusted) | 9.19 | 11.94 | 14.65 | Core basic earnings per share | 18.16 | 21.21 | 23.3 |
| | 2015 | 2016 | 2017 | | 2018 | 2019 | CAGR 2015-19 |
| Operating cash flow | 185.6 | 184.7 | 217.3 | Operating cash flow | 277.1 | 378.5 | 19.5 |
| Capital expenditure | (35.2) | (46.7) | (74.4) | Capital expenditure | (109.7) | (149.8) | |
| as % of revenue | -4.4% | -5.1% | -6.7% | as % of revenue | -8.0% | -9.4% | |
| Free cash flow | 151.1 | 138.7 | 144.7 | Free cash flow | 169.4 | 229.7 | 11.0 |
| Number of employees (year-end) | 3'471 | 3'797 | 4'881 | Number of employees (year-end) | 5'954 | 7'590 | 21.6 |


44

44


straumanngroup

Straumann's currency exposure

Revenue breakdown FY2019¹




Cost breakdown FY2019¹



| Average exchange rates (rounded) | | | | | FX sensitivity (+/- 10%) on full-year | |
|----------------------------------|--------|-------|-------|--------------|---------------------------------------|---------|
| | | 2018 | 2019 | Closing 2019 | Revenue | EBIT |
| 1 | EURCHF | 1.15 | 1.11 | 1.09 | +/- 43m | +/- 23m |
| 1 | USDCHF | 0.98 | 0.99 | 0.97 | +/- 45m | +/- 21m |
| 100 | BRLCHF | 26.9 | 25.1 | 24.1 | +/- 11m | +/- 1m |
| 100 | CNYCHF | 0.147 | 0.144 | 0.139 | +/- 17m | +/- 11m |

Exchange rates development in 2018-19




45

¹ These distribution charts represent the total net revenues and the total COGS, as well as OPEX in the various currencies. All numbers are rounded and based on FY 2019 figures as well as average FX rates in 2018-19. They also include recent acquisitions and new subsidiaries.

straumanngroup

45



Thank You

investor.relations@straumann.com

straumanngroup

46

CORE RESULT RECONCILIATION 2019

| (in CHF 1 000) | IFRS 2019 | PPA amortization | Impairments | Legal cases | Consolidation result former associates | Other | CORE 2019 |
|---|--------------|---------------------|-------------|-------------|--|---------|--------------|
| Revenue | 1 596 225 | | | | | | 1 596 225 |
| Cost of goods sold | (395 749) | 2 484 | | | | 4 272 | (388 992) |
| Gross profit | 1 200 477 | 2 484 | | | | 4 272 | 1 207 233 |
| Other income | 12 807 | | | | | (7 085) | 5 722 |
| Distribution expense | (330 974) | 10 390 | | | | | (320 584) |
| Administrative expense | (495 170) | 6 421 | | 25 500 | | 2 796 | (460 454) |
| Operating profit | 387 140 | 19 294 | | 25 500 | | (17) | 431 917 |
| Finance income | 64 873 | | | | | | 64 873 |
| Finance expense | (89 475) | | | | | | (89 475) |
| Gain on consolidation of former associates | 5 967 | | | | (5 967) | | 0 |
| Share of results of associates | (3 036) | | | | | | (3 036) |
| Profit before income tax | 365 469 | 19 294 | | 25 500 | (5 967) | (17) | 404 279 |
| Income tax expense | (57 440) | (5 416) | | (3 188) | | 5 | (66 039) |
| NET PROFIT | 308 029 | 13 878 | | 22 313 | (5 967) | (13) | 338 240 |
| Attributable to: | | | | | | | |
| Shareholders of the parent company | 306 473 | 13 410 | | 22 313 | (5 967) | (13) | 336 216 |
| Non-controlling interests | 1 556 | 468 | | 0 | 0 | 0 | 2 024 |
| Basic earnings per share (in CHF) | 19.33 | | | | | | 21.21 |
| Diluted earnings per share (in CHF) | 19.26 | | | | | | 21.13 |
| Operating profit | 387 140 | 19 294 | | 25 500 | | (17) | 431 917 |
| Depreciation & amortization | 93 498 | (16 956) | | | | (3 520) | 73 022 |
| EBITDA | 480 637 | 2 338 | | 25 500 | | (3 537) | 504 939 |

CORE RESULT RECONCILIATION 2018

| (in CHF 1 000) | IFRS 2018 | PPA amortization | Impairments | Legal cases | Consolidation result former associates | Other | CORE 2018 |
|---|--------------|---------------------|-------------|-------------|--|-------|--------------|
| Revenue | 1 363 560 | | | | | | 1 363 560 |
| Cost of goods sold | (344 315) | 8 887 | | | | | (335 429) |
| Gross profit | 1 019 245 | 8 887 | | | | | 1 028 132 |
| Other income | 3 424 | | | | | | 3 424 |
| Distribution expense | (291 018) | 10 033 | | | | | (280 984) |
| Administrative expense | (389 016) | 5 871 | | | | | (383 145) |
| Operating profit | 342 635 | 24 791 | | | | | 367 426 |
| Finance income | 72 852 | | | | | | 72 852 |
| Finance expense | (89 802) | | | | | | (89 802) |
| Gain on consolidation of former associates | 10 725 | | | | (10 725) | | 0 |
| Share of results of associates | (9 984) | | 7 688 | | | | (2 296) |
| Profit before income tax | 326 426 | 24 791 | 7 688 | | (10 725) | | 348 180 |
| Income tax expense | (48 639) | (6 611) | 0 | | | | (55 250) |
| Net profit | 277 787 | 18 180 | 7 688 | | (10 725) | | 292 930 |
| Attributable to: | | | | | | | |
| Shareholders of the parent company | 272 770 | 17 585 | 7 688 | | (10 725) | | 287 318 |
| Non-controlling interests | 5 017 | 595 | 0 | | 0 | | 5 612 |
| Basic earnings per share (in CHF) | 17.24 | | | | | | 18.16 |
| Diluted earnings per share (in CHF) | 17.18 | | | | | | 18.09 |
| Operating profit | 342 635 | 24 791 | | | | | 367 426 |
| Depreciation & amortization | 52 367 | (15 980) | | | | | 36 387 |
| EBITDA | 395 002 | 8 811 | | | | | 403 813 |